Evidence map›Paper›PMID 42215629›Full record

Trial reportScientific reports2026

Alcohol consumption and oral human papillomavirus infection among men living with HIV: a cross-sectional study from the ULACNet 201 trial.

Anna Beltrame, Luisa L Villa, Eduardo Lazcano-Ponce, Jorge Santana-Bagur, Betania Allen-Leigh, Alejandra J Portillo-Romero, Vikrant V Sahasrabuddhe, Margaret G House, Emma Brofsky, Lenice Galan de Paula and 9 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04255849 (Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04255849 phase3active not recruitingnot on this map

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2021 to 2026Enrolled700ConditionsHPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV InfectionArms9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Saline Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Anna BeltrameCenter for Immunization and Infection Research in Cancer (CIIRC), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. anna.beltrame@moffitt.org.
Luisa L VillaUniversidade de São Paulo Faculdade de Medicina (FMUSP) Instituto do Cancer Estado de São Paulo, São Paulo, Brazil.
Eduardo Lazcano-PonceNational Institute of Public Health, Cuernavaca, Morelos, Mexico.
Jorge Santana-BagurThe University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
Betania Allen-LeighNational Institute of Public Health, Cuernavaca, Morelos, Mexico.
Alejandra J Portillo-RomeroNational Institute of Public Health, Cuernavaca, Morelos, Mexico.
Vikrant V SahasrabuddheDivision of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Margaret G HouseDivision of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Emma BrofskyDivision of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Lenice Galan de PaulaUniversidade de São Paulo Faculdade de Medicina (FMUSP) Instituto do Cancer Estado de São Paulo, São Paulo, Brazil.
Roberto Carvalho da SilvaCentro de Referencia e Treinamento em DST e AIDS, São Paulo, Brazil.
Wenyi FanBiostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Michael J SchellBiostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Julie RathwellCenter for Immunization and Infection Research in Cancer (CIIRC), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Kimberly Isaacs-SorianoCenter for Immunization and Infection Research in Cancer (CIIRC), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Caique MelloDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.
Grant B EllsworthDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Timothy Wilkin *Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA. twilkin@health.ucsd.edu.
Anna R Giuliano *Center for Immunization and Infection Research in Cancer (CIIRC), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico - Supplemental ExtensionU54CA242639 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELLSWORTH, GRANT B., GIULIANO, ANNA R. · 2019 to 2025
$9.4M
American Cancer Society CRP-23-1010710-06-COUNCCR NIH HHS P30-CA076292NCI NIH HHS P30 CA076292NCI NIH HHS U54 CA242639
6 · The paper itself

Abstract

Alcohol consumption is recognized as a risk factor for oropharyngeal cancer. However, its role in oral human papillomavirus (HPV) infection among people living with HIV (PLWH) remains unclear. This cross-sectional study analyzed baseline data from 699 men living with HIV (MLWH) enrolled in the multicenter ULACNet-201 trial (NCT04255849) to assess oral HPV infection by drinking behavior, examine the association between alcohol consumption and HPV infection, exploring smoking as a potential effect modifier. Oral gargle specimens were tested for high-risk (HR-HPV) and low-risk (LR-HPV) HPV genotypes using SPF10 PCR-DEIA-LiPA25. Logistic regression estimated adjusted odds ratios (ORs, 95% CIs) controlling for key covariates and explored heterogeneity by smoking status. Alcohol use in the past month was reported by 76.4% of participants, with 6% classified as heavy drinkers and 27% as binge drinkers. Oral HPV infection was similar between drinkers and nondrinkers (27.7% vs. 28.5%), with comparable rates for HR-HPV (11% vs. 10.9%) and LR-HPV (18.7% vs. 19.7%). Alcohol consumption was not associated with HR-HPV overall, and exploratory analysis found no evidence of effect modification by smoking status. A possible interaction between alcohol consumption and smoking status was observed for LR-HPV, but these findings should be interpreted cautiously. Further longitudinal studies are needed.

Indexed as

Alcohol DrinkingHIV InfectionsHuman Papillomavirus VirusesMouth DiseasesPapillomavirus InfectionsAdultCross-Sectional StudiesHumansMaleMiddle AgedPapillomaviridaeRisk FactorsSmokingDrinkingEffect modificationOral HPVOropharyngeal cancerSmokingStratification

Identifiers

PMID42215629
PMCPMC13407872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.